ReviewJACC. Asia2026
Redefining Uric Acid and Cardiovascular Risk: Vascular Gout and Crystal-Driven Vascular Inflammation in Asymptomatic Hyperuricemia.
Review in JACC. Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urate-lowering trials have not consistently demonstrated benefits in preventing coronary events, revealing an interventional gap and challenging the causal role of uric acid in cardiovascular disease. Advances in dual-energy computed tomography have revealed monosodium urate crystal deposition within vessel walls and atherosclerotic plaques, leading to the concept of vascular gout. Persistent hyperuricemia, particularly in Asian populations characterized by urate underexcretion, may facilitate crystal deposition and innate immune pathway activation. These inflammatory processes may promote vascular inflammation, plaque instability, and cardiovascular events. Xanthine oxidase inhibition effectively lowers serum uric acid levels and reduces monosodium urate crystal burden in articular tissues. However, whether urate-lowering therapy reduces monosodium urate crystal deposition and crystal-driven inflammation within the vascular wall remains unknown. Therefore, we aimed to reframe uric acid from a metabolic marker to a mediator of urate crystal-driven vascular inflammation and discuss future therapeutic strategies targeting crystal burden and inflammation in Asian populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.